- Home
- IDYA vs RARE Comparison
IDYA vs RARE Comparison
Compare IDYA & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- RARE
- Stock Information
- Founded
- IDYA 2015
- RARE 2010
- Country
- IDYA United States
- RARE United States
- Employees
- IDYA N/A
- RARE N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- IDYA Health Care
- RARE Health Care
- Exchange
- IDYA Nasdaq
- RARE Nasdaq
- Market Cap
- IDYA 2.9B
- RARE 3.2B
- IPO Year
- IDYA 2019
- RARE 2014
- Fundamental
- Price
- IDYA $34.21
- RARE $33.71
- Analyst Decision
- IDYA Buy
- RARE Strong Buy
- Analyst Count
- IDYA 14
- RARE 14
- Target Price
- IDYA $49.58
- RARE $87.71
- AVG Volume (30 Days)
- IDYA 992.0K
- RARE 1.4M
- Earning Date
- IDYA 11-04-2025
- RARE 11-04-2025
- Dividend Yield
- IDYA N/A
- RARE N/A
- EPS Growth
- IDYA N/A
- RARE N/A
- EPS
- IDYA N/A
- RARE N/A
- Revenue
- IDYA $214,834,000.00
- RARE $630,598,000.00
- Revenue This Year
- IDYA $90.17
- RARE $19.65
- Revenue Next Year
- IDYA $217.29
- RARE $23.65
- P/E Ratio
- IDYA N/A
- RARE N/A
- Revenue Growth
- IDYA 5377.66
- RARE 20.63
- 52 Week Low
- IDYA $13.45
- RARE $25.81
- 52 Week High
- IDYA $34.66
- RARE $50.00
- Technical
- Relative Strength Index (RSI)
- IDYA 68.23
- RARE 54.99
- Support Level
- IDYA $31.15
- RARE $31.00
- Resistance Level
- IDYA $34.66
- RARE $34.01
- Average True Range (ATR)
- IDYA 1.58
- RARE 1.68
- MACD
- IDYA 0.11
- RARE -0.11
- Stochastic Oscillator
- IDYA 89.86
- RARE 93.46
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.